24 January 2014

TiGenix to sell Dutch manufacturing facility to PharmaCell

Leuven (BELGIUM) – January 24, 2014 – TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it has signed an agreement for the sale of its stateof- the-art Dutch production facility to PharmaCell B.V for a total consideration of EUR 5.75 million.PharmaCell, a leading European-based contract manufacturing organization active in the area of cell therapy and regenerative medicine, is to acquire the shares of TiGenix’s wholly owned subsidiary TiGenix B.V., which holds the Dutch manufacturing facility.

Under the terms of the agreement, TiGenix will receive an upfront payment of EUR 3.5 million when the sale becomes effective and a final payment of EUR 750,000 after three years. In addition, ChondroCelect will continue to be manufactured at the facility under a long-term manufacturing agreement, under the terms of which TiGenix will benefit from a cost relief of EUR 1.5 million during the first three years, the largest portion of which will fall in the first year.

The sale of TiGenix B.V. is expected to become effective in the coming months. Closing of the transaction is subject to confirmation by the relevant authority that TiGenix B.V. is authorized to produce other products than ChondroCelect, as well as confirmation in respect of the financing of the transaction by PharmaCell.

“The agreement with PharmaCell reduces our organizational complexity and eliminates an important part of our fixed costs while keeping intact the continuity of our product supply,” said Eduardo Bravo, CEO of TiGenix. “We keep diligently delivering on our action plan and securing the means to be able to execute our strategy.”

In 2012, TiGenix’s state-of-the-art manufacturing facility in Sittard Geleen, the Netherlands, successfully passed cGMP inspection by the Dutch authorities, and obtained approval from the European Medicines Agency for the production of ChondroCelect, the company’s commercial cell therapy product for cartilage repair in the knee.

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed cell therapy product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.

Forward-looking information
This press release is for information purposes only and is not intended to constitute, and should not be construed as, an offer to sell or a solicitation of any offer to buy shares in the share capital of TiGenix NV (the “Company”). This announcement has been issued by and is the sole responsibility of the Company.

Certain statements in this press release, as well as oral statements that may be made by the Company or by officers, directors or employees acting on their behalf relating to the subject matter hereof, may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. Forward-looking statements may be identified by references to strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors, many of which are difficult to predict and generally beyond the control of the Company. Forward looking statements may and often do differ materially from actual results. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. Forward-looking statements speak only as of the date they are made. The Company expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.

For more information:

Eduardo Bravo
Chief Executive


Claudia D’Augusta
Officer Chief Financial Officer


Hans Herklots
Director Investor & Media Relations
+32 16 39 60 97